Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 remibrutinib in chronic spontaneous urticaria inadequately controlled by H1-antihistamines
jRCT2031210408Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Novartis. Primary endpoints: Change from baseline in UAS7 at Week 12, Change from baseline in ISS7 at Week 12 and 1 more. Started Dec 2021; status: completed.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2031210408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210408.